Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.

Abstract

BACKGROUND Neuroblastoma is a pediatric malignancy, and most tumor cells express the norepinephrine transporter (NET) enabling uptake of NET ligands. Meta-iodobenzylguanidine (MIBG) is a NET-specific ligand used as a highly specific imaging agent and targeted radiotherapeutic. Patients with neuroblastoma frequently require sedation during targeted… (More)
DOI: 10.1002/pbc.26268

Topics

Cite this paper

@article{Batra2017DexmedetomidineDN, title={Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.}, author={Vandana Batra and Mehran Makvandi and Athena F. Zuppa and Neil Patel and Jimmy Elias and Daniel A. Pryma and John M. Maris}, journal={Pediatric blood & cancer}, year={2017}, volume={64 4} }